A Phase 1 interventional study of HD-P023 and Teneligliptin in Healthy Volunteers, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Handok Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet of HD-P023 by oral
Drug: HD-P023
One tablet each of Teneligliptin and Empagliflozin High by oral
Drug: Teneligliptin · Drug: Empagliflozin
Single dose administration of HD-P023
Single does administration of Teneligliptin and Empagliflozin High
Single does administration of Teneligliptin and Empagliflozin High
Area under the plasma concentration versus time curve (AUCt) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Peak Plasma Concentration (Cmax) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Area under the plasma concentration versus time curve zero to time infinity (AUC∞) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Ratio of AUCt and AUC∞ (AUCt/AUC∞) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Time to peak drug concentration (Tmax) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Volume of distribution (VZ/F) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Clearance (CL/F) of Teneligliptin and Empagliflozin
Time frame: 72 hours
Ran from May 2024 to primary completion in Jun 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.